

<b>NCT ID</b>	NCT04595266
<b>Title</b>	Chemoembolization (Lifepearls-Irinotecan) in Patients With Colorectal Cancer and Metastatic Disease
<b>Phase</b>	Phase 2
<b>Date Added</b>	2020-10-20
<b>Location</b>	Spain
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	Anti-EGFR or Bevacizumab, FOLFOX regimen, LIVERPEARLS-Irinotecan
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp

---

<b>NCT ID</b>	NCT04589845
<b>Title</b>	Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
<b>Phase</b>	Phase 2
<b>Date Added</b>	2020-10-19

<b>Location</b>	Alabama, United States
	Arizona, United States
	California, United States
	Colorado, United States
	Delaware, United States
	Florida, United States
	Georgia, United States
	Idaho, United States
	Illinois, United States
	Indiana, United States
	Maine, United States
	Maryland, United States
	Michigan, United States
	Minnesota, United States
	Missouri, United States
	Montana, United States
	Nebraska, United States
	Nevada, United States
	New Hampshire, United States
	New Jersey, United States
	New Mexico, United States
	New York, United States
	Ohio, United States
	Oregon, United States
	Pennsylvania, United States
	South Carolina, United States
	Tennessee, United States
	Texas, United States
	Washington, United States
	Wisconsin, United States
	Australia
	Belgium
	Brazil
	Canada
	China
	Denmark
	France
	Germany
	Hong Kong
	Israel
	Italy
	Japan
	New Zealand
	Poland
	Portugal
	Puerto Rico
	Singapore
	South Africa
	South Korea
	Spain
	Switzerland
	Taiwan
	United Kingdom
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	No
<b>Status</b>	Recruiting
<b>Drugs</b>	Alectinib, Atezolizumab, Belvarafenib, Entrectinib, Idasanutlin, Inavolisib, Ipatasertib, Pralsetinib, Trastuzumab emtansine
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<hr/>	
<b>NCT ID</b>	NCT04591431
<b>Title</b>	The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy
<b>Phase</b>	Phase 2
<b>Date Added</b>	2020-10-19

<b>Location</b>	Italy
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	No
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	Alectinib, Atezolizumab, Brigatinib, Cobimetinib, Entrectinib, Erlotinib, everolimus, Ipatasertib, Ipilimumab, Itacitinib, Lapatinib, Nivolumab, Oncology Drugs, palbociclib, Pemigatinib, Pertuzumab, Ponatinib, Trastuzumab, Trastuzumab emtansine, Vemurafenib, Vismogedib
<b>Tags</b>	MSS/ MMRp

---

<b>NCT ID</b>	NCT04575922
<b>Title</b>	Nivolumab+Ipilimumab+RT in MSS mCRC
<b>Phase</b>	Phase 2
<b>Date Added</b>	2020-10-05
<b>Location</b>	Massachusetts, United States
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	Yes
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	Ipilimumab, Nivolumab
<b>Tags</b>	MSS/ MMRp

---

<b>NCT ID</b>	NCT04550897
<b>Title</b>	A Phase I/II Study With BM7PE Immunotoxin in Colorectal Cancer Patients
<b>Phase</b>	Phase 1
<b>Date Added</b>	2020-09-16
<b>Location</b>	Norway
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	Yes
<b>Status</b>	Recruiting
<b>Drugs</b>	BM7PE
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp

---

<b>NCT ID</b>	NCT04535024
<b>Title</b>	The Combination of Immunotherapy and Stereotactic Ablative Radiotherapy in MSS Oligometastatic Colorectal Cancer
<b>Phase</b>	Phase 2
<b>Date Added</b>	2020-09-01
<b>Location</b>	China
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Recruiting
<b>Drugs</b>	Sintilimab
<b>Tags</b>	MSS/ MMRp

---

<b>NCT ID</b>	NCT04483219
<b>Title</b>	Tyrosine Kinase Inhibitor (TKI) + Anti-PD-1 Antibody in TKI-responded Microsatellite Stability/Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Adenocarcinoma.
<b>Phase</b>	Phase 2
<b>Date Added</b>	2020-07-23
<b>Location</b>	China
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	Yes
<b>Status</b>	Unknown status

<b>Drugs</b>	TKI ± anti-PD-1 antibody
<b>Tags</b>	MSS/ MMRp
<b>NCT ID</b>	NCT04444622
<b>Title</b>	Immunotherapy for Third Line Metastatic Colorectal Cancer
<b>Phase</b>	Phase 2
<b>Date Added</b>	2020-06-23
<b>Location</b>	Florida, United States Michigan, United States New Jersey, United States New York, United States
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Completed
<b>Drugs</b>	
<b>Tags</b>	MSS/ MMRp
<b>NCT ID</b>	NCT04432857
<b>Title</b>	AN0025 and Pembrolizumab Combination in Advanced Solid Tumors
<b>Phase</b>	Phase 1
<b>Date Added</b>	2020-06-16
<b>Location</b>	Missouri, United States Texas, United States Utah, United States Virginia, United States France
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	AN0025, Pembrolizumab
<b>Tags</b>	MSS/ MMRp
<b>NCT ID</b>	NCT04426669
<b>Title</b>	A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering
<b>Phase</b>	Phase 1
<b>Date Added</b>	2020-06-11
<b>Location</b>	Minnesota, United States
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	Yes
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	Aldesleukin, Cyclophosphamide, Fludarabine, Tumor Infiltrating Lymphocytes (TIL)
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp